BMS-214662

BMS-214662 is a farnesyl transferase inhibitor. BMS-214662 can effectively block the localization and function of Ras protein in the cell membrane by inhibiting the pro-group modification of Ras protein, thereby exerting anti-tumor activity. BMS-214662 has an IC50 value of 1.3 nM for H-Ras and 8.4 nM for K-Ras. BMS-214662 can be used to study Ras-related tumor diseases[1][2].

Product Specifications

CAS Number

[195987-41-8]

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

Farnesyl Transferase; Ras

Type

Reference compound

Related Pathways

GPCR/G Protein; MAPK/ERK Pathway; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/BMS-214662.html

Purity

99.86

Solubility

DMSO : ≥ 100 mg/mL

Smiles

N#CC1=CC=C(N(CC2=CN=CN2)C[C@@H](CC3=CC=CC=C3)N(S(=O)(C4=CC=CS4)=O)C5)C5=C1

Molecular Formula

C25H23N5O2S2

Molecular Weight

489.61

Precautions

H302, H315, H319

References & Citations

[1]Hunt JT, et al. Discovery of (R) -7-cyano-2,3,4, 5-tetrahydro-1- (1H-imidazol-4-ylmethyl) -3- (phenylmethyl) -4- (2-thienylsulfonyl) -1H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity. J Med Chem. 2000 Oct 5;43 (20) :3587-95.|[2]Rose WC, et al. Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor. Cancer Res. 2001 Oct 15;61 (20) :7507-17.